CY1113556T1 - PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors - Google Patents

PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors

Info

Publication number
CY1113556T1
CY1113556T1 CY20131100067T CY131100067T CY1113556T1 CY 1113556 T1 CY1113556 T1 CY 1113556T1 CY 20131100067 T CY20131100067 T CY 20131100067T CY 131100067 T CY131100067 T CY 131100067T CY 1113556 T1 CY1113556 T1 CY 1113556T1
Authority
CY
Cyprus
Prior art keywords
pyrozine
pyridene
producers
oxidation inhibitors
nadph oxidation
Prior art date
Application number
CY20131100067T
Other languages
Greek (el)
Inventor
Patrick Page
Mike Orchard
Laetitia Fioraso-Cartier
Bianca Mottironi
Original Assignee
Genkyotex Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genkyotex Sa filed Critical Genkyotex Sa
Publication of CY1113556T1 publication Critical patent/CY1113556T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Η παρούσα εφεύρεση αναφέρεται σε παράγωγα πυραζολο πυριδίνης του Τύπου (Ι), σε φαρμακευτική σύνθεση αυτών και στη χρήση τους για τη θεραπευτική αγωγή ή/και προφύλαξη από διαταραχές ή καταστάσεις που σχετίζονται με ανηγμένη μορφή του φωσφορικού νικοτιναμιδο αδενινο δινουκλεοτιδίου-οξειδάση (NADPH Οξειδάση).The present invention relates to pyrazole pyridine derivatives of Formula (I), to a pharmaceutical composition thereof and to their use for the treatment and / or prophylaxis of disorders or conditions associated with a reduced form of nicotinamide adenine dinucleotide (N-Oxidase) Oxidase N-Oxidase). .

CY20131100067T 2007-03-22 2013-01-23 PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors CY1113556T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89628407P 2007-03-22 2007-03-22
EP07109555A EP2002835A1 (en) 2007-06-04 2007-06-04 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP08718102A EP2139477B1 (en) 2007-03-22 2008-03-20 Pyrazolo pyridine derivatives as nadph oxidase inhibitors

Publications (1)

Publication Number Publication Date
CY1113556T1 true CY1113556T1 (en) 2016-06-22

Family

ID=38653574

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100067T CY1113556T1 (en) 2007-03-22 2013-01-23 PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors
CY20141100820T CY1115633T1 (en) 2007-03-22 2014-10-09 PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20141100820T CY1115633T1 (en) 2007-03-22 2014-10-09 PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors

Country Status (18)

Country Link
US (2) US8389518B2 (en)
EP (3) EP2002835A1 (en)
JP (2) JP5715340B2 (en)
CN (2) CN101686967B (en)
AU (1) AU2008228186C1 (en)
BR (1) BRPI0808824B8 (en)
CA (1) CA2676954C (en)
CY (2) CY1113556T1 (en)
DK (2) DK2139477T3 (en)
ES (2) ES2398994T3 (en)
HK (2) HK1141734A1 (en)
HR (2) HRP20130143T1 (en)
IL (1) IL201009A (en)
PL (2) PL2139477T3 (en)
PT (2) PT2545918E (en)
RS (2) RS52640B (en)
SI (2) SI2139477T1 (en)
WO (1) WO2008113856A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2002835A1 (en) * 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2000176A1 (en) 2007-06-04 2008-12-10 GenKyo Tex Tetrahydroindole derivatives as NADPH Oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US20120141461A1 (en) * 2009-07-17 2012-06-07 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating fibrotic disorders
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2512242B8 (en) * 2009-12-18 2015-12-09 GlaxoSmithKline Intellectual Property Limited Novel compounds
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
WO2012173952A1 (en) 2011-06-13 2012-12-20 Emory University Piperazine derivatives, compositions, and uses related thereto
GB2494679A (en) * 2011-09-15 2013-03-20 Univ Jw Goethe Frankfurt Main Treatment of neuropathic pain and nerve injury by Nox4 inhibition
EP2591782A1 (en) * 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof
WO2014153227A1 (en) 2013-03-14 2014-09-25 Eastern Virginia Medical School Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting nox-1
EP2857399A1 (en) 2013-10-03 2015-04-08 GenKyoTex SA Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction
EP3098220A1 (en) 2015-05-28 2016-11-30 GenKyoTex SA Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof
CA2989098A1 (en) * 2015-06-22 2016-12-29 Actelion Pharmaceuticals Ltd Nadph oxidase 4 inhibitors
US11084796B2 (en) 2016-05-10 2021-08-10 Georgia State University Research Foundation, Inc. Heterocyclic derivatives for the treatment of RSV
CA3027097C (en) * 2016-05-10 2023-11-28 Georgia State University Research Foundation, Inc. Bicyclic fused pyrazole derivatives for the treatment of rsv
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
KR102507967B1 (en) 2016-09-09 2023-03-09 인사이트 코포레이션 Pyrazolopyridine derivatives as HPK1 modulators and their use to treat cancer
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018203298A1 (en) 2017-05-04 2018-11-08 Glenmark Pharmaceuticals S.A. Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
WO2019023448A1 (en) 2017-07-26 2019-01-31 Emory University Nadph oxidase inhibitors and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
MX2020008656A (en) 2018-02-20 2020-12-09 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer.
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
CN109846900B (en) * 2018-05-25 2021-07-23 四川大学 Application of reduced nicotinamide adenine dinucleotide phosphate in preparation of antiviral drugs
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US20220112187A1 (en) * 2018-09-11 2022-04-14 Hoffmann-La Roche Inc. Pyrazolopyridine amine compounds for the treatment of autoimmune disease
JP7399968B2 (en) 2018-09-25 2023-12-18 インサイト・コーポレイション Pyrazolo[4,3-D]pyrimidine compounds as ALK2 and/or FGFR modulators
CN114450276A (en) 2019-08-06 2022-05-06 因赛特公司 Solid forms of HPK1 inhibitor
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931407A (en) 1973-03-01 1976-01-06 American Hoechst Corporation Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent
DE3728278A1 (en) 1986-12-17 1988-06-23 Bayer Ag HERBICIDES AND FUNGICIDES ON THE BASIS OF SUBSTITUTED PYRAZOLIN-5-ON DERIVATIVES
DE19518082A1 (en) 1995-05-17 1996-11-21 Merck Patent Gmbh 4 (-Arylaminomethylene) -2,4-dihydropyrazol-3-one
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
IL144468A0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
JP4196678B2 (en) 2001-04-26 2008-12-17 味の素株式会社 Heterocyclic compounds
EP1291017A3 (en) 2001-09-10 2003-07-02 Warner-Lambert Company Use of statins to inhibit formation of osteoclasts
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
AU2003267980A1 (en) 2002-07-03 2004-01-23 Janssen Pharmaceutica, N.V. Substituted heteroaryl and heterocyclic compounds useful in treating inflammatory disorders
AU2004216541A1 (en) 2003-02-28 2004-09-10 Howard Florey Institute Of Experimental Physiology And Medicine Therapeutic compositions
JPWO2004089412A1 (en) 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 Specific NAD (P) H oxidase inhibitor
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006041874A2 (en) 2004-10-04 2006-04-20 Myriad Genetics, Inc. Compounds for alzheimer's disease
FR2882654B1 (en) 2005-03-01 2007-04-27 Servier Lab USE OF DIOSMETIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF THROMBOTIC DISEASES
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US20070014739A1 (en) 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
DE102005048897A1 (en) * 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Diacylindazole derivatives as inhibitors of lipases and phospholipases
AU2007234399A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2000176A1 (en) 2007-06-04 2008-12-10 GenKyo Tex Tetrahydroindole derivatives as NADPH Oxidase inhibitors
TW200930713A (en) 2007-12-03 2009-07-16 Takeda Pharmaceutical Nitrogen-containing heterocyclic compound and use thereof
US20090163452A1 (en) 2007-12-20 2009-06-25 Schwartz Janice B Compositions and methods for lowering serum cholesterol
FR2929276B1 (en) 2008-04-01 2010-04-23 Servier Lab NOVEL DIOSMETIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2521453B1 (en) 2010-01-08 2016-05-11 Beth Israel Deaconess Medical Center Combinations of vitamin d and a statin for the treatment of migraine headaches
EP2361912A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2591782A1 (en) 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof

Also Published As

Publication number Publication date
HRP20141029T1 (en) 2014-12-19
ES2512491T3 (en) 2014-10-24
JP2015134805A (en) 2015-07-27
JP5715340B2 (en) 2015-05-07
US20100048560A1 (en) 2010-02-25
US9073919B2 (en) 2015-07-07
RS53641B1 (en) 2015-04-30
JP2010521522A (en) 2010-06-24
BRPI0808824B1 (en) 2020-10-13
EP2545918B1 (en) 2014-08-06
BRPI0808824B8 (en) 2021-05-25
EP2139477B1 (en) 2012-12-12
CA2676954A1 (en) 2008-09-25
WO2008113856A1 (en) 2008-09-25
SI2139477T1 (en) 2013-02-28
AU2008228186A1 (en) 2008-09-25
CN105061422B (en) 2019-07-12
HK1141734A1 (en) 2010-11-19
DK2139477T3 (en) 2013-03-11
CN101686967B (en) 2015-08-19
RS52640B (en) 2013-06-28
ES2398994T3 (en) 2013-03-25
IL201009A0 (en) 2010-05-17
HRP20130143T1 (en) 2013-03-31
SI2545918T1 (en) 2014-12-31
US8389518B2 (en) 2013-03-05
PT2139477E (en) 2013-02-07
AU2008228186C1 (en) 2012-12-06
BRPI0808824A2 (en) 2014-08-19
CY1115633T1 (en) 2017-01-04
DK2545918T3 (en) 2014-11-10
PT2545918E (en) 2014-11-03
IL201009A (en) 2016-03-31
PL2139477T3 (en) 2013-05-31
AU2008228186B2 (en) 2012-06-14
PL2545918T3 (en) 2015-03-31
HK1179871A1 (en) 2013-10-11
EP2139477A1 (en) 2010-01-06
CN101686967A (en) 2010-03-31
CN105061422A (en) 2015-11-18
EP2545918A1 (en) 2013-01-16
JP6047189B2 (en) 2016-12-21
CA2676954C (en) 2016-01-12
EP2002835A1 (en) 2008-12-17
US20130123256A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
CY1115633T1 (en) PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors
CY1114879T1 (en) PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors
CY1115952T1 (en) PYRIDOLINE PYRASOLINE PRODUCERS AS NADRI OXIDATION INHIBITIONS
CY1119780T1 (en) PYRAZOLINODIONI PRODUCERS AS NADPH oxidation inhibitors
NO20083726L (en) Spiroindolinone derivatives
CY1113727T1 (en) Pyridin-4-yl derivatives as immunomodulatory agents
CR20110077A (en) DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANO-2,3,4-TRIOL
BR112012020736A2 (en) pyrazole diperidine derivatives as nadph oxidase inhibitors.
MX350809B (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication.
BR112012020742A2 (en) pyrazole piperidine derivatives as nadph oxidase inhibitors.
MA32467B1 (en) GPCR AGONISTS PIPERIDINYL DERIVATIVES
CY1115043T1 (en) pharmaceutical product
MA32723B1 (en) Anilino-pyrimidine derivatives substituted with sulfoximine marked as CDK inhibitors, their preparation and use as drugs
CY1112077T1 (en) PIRPENENIDONE TREATMENT AVOID FLUVOXAMIN
MX2015013687A (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors.
DE602007011902D1 (en) SPIROINDOLINON DERIVATIVES
CR20110013A (en) Heteroaryl Derivatives as DGAT1 Inhibitors
UA109525C2 (en) ALKYLAMIDE COMPOUND AND ITS APPLICATIONS
CY1116775T1 (en) Pyrimidone derivatives as inhibitors of viral transglutaminase
CY1116168T1 (en) TOY CCR3 HYPERCELLULATORS AND SALT SALTS
CY1111954T1 (en) TETRAHYDRONALPHALINE PRODUCTS, METHODS FOR PRODUCING THESE AND USING THESE AS ANTI-FLAMMON
CR11423A (en) NEW SSH INHIBITORS AND THEIR USE
UA112556C2 (en) INSECTICID DERIVATIVES OF 2-METOXYBENZAMIDES
CY1113240T1 (en) Salts of HIV Inhibitor Compounds
NO20071805L (en) Alkylidentetrahydronaphthalene derivatives, processes for their preparation and their use as inflammatory inhibitors.